Novo Nordisk, Medicare Agree on Lower Semaglutide Price

Novo Nordisk, a pharmaceutical giant, has agreed to a lower price for semaglutide, the key ingredient in Ozempic and Wegovy, as part of the U.S. Inflation Reduction Act. This move, effective in 2027, comes after speculation of price reductions for weight-loss medications in exchange for Medicare coverage. While the exact price is undisclosed, Novo Nordisk's stock initially dipped but later rebounded, reflecting market relief that the price cut wasn't as severe as anticipated. This agreement marks a significant shift in drug pricing in the U.S. The Daily News Now! - Every city. Every story. AI Powered. Hosted on Acast. See acast.com/privacy for more information.